Marex Group’s Dyne Therapeutics DYN Stock Holding History

Marex Group’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,500	Closed	-$724K	–	656
2024 Q1	$724K	Buy	+25,500	New	+$577K	0.02%	210

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marex Group's DYN Position: Q2 2024 in Review

Marex Group sold out of Dyne Therapeutics (DYN) in Q2 2024, closing a stake of 25,500 shares — an estimated $724K sold.

Marex Group first reported a position in DYN in Q1 2024 and held it in 1 quarter. The position peaked at $724K in Q1 2024. 193 funds tracked by Wall St. Rank hold DYN as of Q2 2024.

Marex Group reported no remaining Dyne Therapeutics position as of Q2 2024 after selling out during the quarter.
Marex Group sold 25,500 Dyne Therapeutics shares in Q2 2024, an estimated $724K.
Marex Group first reported a position in Dyne Therapeutics in Q1 2024 and held it in 1 quarter.
Marex Group's Dyne Therapeutics position peaked at $724K in Q1 2024.
193 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2024.

Based on Marex Group's 13F filing for Q2 2024, filed 2 Apr 2026.